Quantum Biopharma Ltd. Subordinate Voting Shares Class B

As of June 30, 2026, Quantum Biopharma Ltd. Subordinate Voting Shares Class B carries a market capitalization of 39.02M, placing it among publicly traded companies globally. Its enterprise value stands at 32.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Quantum Biopharma Ltd. Subordinate Voting Shares Class B's next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Quantum Biopharma Ltd. Subordinate Voting Shares Class B has 7.58M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Quantum Biopharma Ltd. Subordinate Voting Shares Class B maintains a current ratio of 1.20, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.81, indicating elevated leverage, while an interest coverage ratio of -4.82 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Quantum Biopharma Ltd. Subordinate Voting Shares Class B posted a negative return on equity (ROE) of -429.58, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -169.48, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 7.00, a quick read on workforce productivity versus industry peers.

As of the close on September 4, 2026, Quantum Biopharma Ltd. Subordinate Voting Shares Class B's stock has declined approximately 77.50% over the past 52 weeks. The 50-day moving average sits at 4.65, while the 200-day moving average is 6.97.

Over the twelve months ended June 30, 2026, Quantum Biopharma Ltd. Subordinate Voting Shares Class B generated - - in revenue and converted that into -35.71M in net income, yielding earnings per share of -7.63. EBITDA reached -2.17M, while operating income came in at -17.33M.

As of June 30, 2026, Quantum Biopharma Ltd. Subordinate Voting Shares Class B holds 5.48M in cash and equivalents against 1.37M in total debt, resulting in a net debt position of -3.90M. Total book value stands at 11.28M, with working capital of 2.36M providing operational flexibility.

Quantum Biopharma Ltd. Subordinate Voting Shares Class B produced -7.79M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -32.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -40.49, meaning Quantum Biopharma Ltd. Subordinate Voting Shares Class B raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Quantum Biopharma Ltd. Subordinate Voting Shares Class B's most recent stock split took place on August 15, 2024 with a 65:1 split ratio.

As of June 30, 2026, Quantum Biopharma Ltd. Subordinate Voting Shares Class B has an Altman Z-Score of -31.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.